Chronic myelogenous leukemia

Chronic myelogenous leukemia (synonym chronic myelosis) is characterized by enhanced reproduction in the bone marrow myeloid cells with delayed maturation; in the peripheral blood, along with Mature leukocytes meet intermediate forms myeloid series - promyelocyte and plasmic order has been revealed. Myeloid infiltration develops in the spleen, liver and other organs. The disease for a long time, there are no symptoms and are diagnosed at a random blood test (moderate increase the number of cells and the presence of promielozitov and plasmic order has been revealed). In the period expressed events marked weakness, bone pain, sweating, low-grade fever, sharply enlarged liver and spleen, feeling of heaviness in the stomach and pain in the spleen. The condition of patients is getting progressively worse. Appear waxy pallor, exhaustion, bleeding in the skin and mucous membranes, high fever with chills and drenching sweat. Increasing cardiovascular failure (shortness of breath, tachycardia, hypotension , and others). Sharply reduced resistance to all kinds of infections. Pneumonia, tuberculosis, fungal and purulent lesions become fatal for the sick. Blood is gradually increasing the number of leukocytes (up to 300 000 - 500 000 to 1 mm3 blood), mainly promielozitov and plasmic order has been revealed increases the percentage of eosinophils and basophils. In the terminal stage of the disease in the blood prevail blast forms, increases anemia, simultaneously sharply reduced the number of platelets. In punctate bone marrow as the progression of illness increases the number of immature cells and decreases the number of red cells in the series.
The diagnosis of chronic myeloid leukemia is put on the basis of clinical and research of the blood and bone marrow.
The forecast is unfavorable, despite rational treatment. Average duration of life from the moment of detection of the disease 3-3,5 years, with slowly progressive course - up to 6 years.
Treatment of patients is carried out in the hospital. As an anti-leukemia funds use mielosan (6-8 mg / day), Doan (8-10 mg 1 time in 4-5 days), 6-mercaptopurine, if indicated - radiation therapy.